Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to establish the maximum tolerated dose of PURETHAL Mites that is
achieved by 90% of the patients with less than 20% of the injections giving rise to a
swelling of > 5 cm and the optimal regimen to reach this maximum dose will be determined.